Profile data is unavailable for this security.
About the company
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
- Revenue in USD (TTM)342.80m
- Net income in USD-465.95m
- Incorporated--
- Employees1.80k
- LocationLegend Biotech Corp2101 Cottontail LaneSOMERSET 08873United StatesUSA
- Phone+1 (732) 317-5050
- Websitehttps://investors.legendbiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.79bn | 376.00 | -- | 6.61 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Tempus AI Inc | 562.02m | -293.25m | 5.93bn | -- | -- | -- | -- | 10.55 | -1.78 | -1.78 | 3.41 | -2.06 | -- | -- | -- | -- | -- | -- | -- | -- | 54.25 | -- | -39.94 | -- | 1.13 | -16.02 | 4.19 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
Revolution Medicines Inc | 4.57m | -484.27m | 6.17bn | 411.00 | -- | 3.57 | -- | 1,350.68 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Cytokinetics, Inc. | 3.75m | -530.60m | 6.36bn | 423.00 | -- | -- | -- | 1,696.19 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Exelixis Inc | 1.85bn | 205.05m | 6.45bn | 1.31k | 34.26 | 3.07 | 28.02 | 3.49 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 6.53bn | 373.00 | 21.22 | 36.69 | 16.29 | 7.57 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 6.59bn | 927.00 | -- | 22.20 | -- | 8.48 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Blueprint Medicines Corp | 282.21m | -288.29m | 6.91bn | 645.00 | -- | 22.23 | -- | 24.49 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.51bn | 355.00 | -- | 13.29 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
Exact Sciences Corp | 2.53bn | -240.23m | 7.97bn | 6.50k | -- | 2.53 | -- | 3.14 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Legend Biotech Corp (ADR) | 342.80m | -465.95m | 8.16bn | 1.80k | -- | 7.01 | -- | 23.79 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Vaxcyte Inc | 0.00 | -436.82m | 8.27bn | 254.00 | -- | 4.17 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 10.38bn | 20.00k | 23.64 | 2.85 | 13.42 | 2.52 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Insmed Inc | 315.49m | -746.89m | 10.52bn | 912.00 | -- | -- | -- | 33.34 | -5.23 | -5.23 | 2.20 | -3.13 | 0.2357 | 0.8971 | 9.32 | 345,936.40 | -55.80 | -40.96 | -72.23 | -46.88 | 78.07 | 77.99 | -236.74 | -212.92 | 1.61 | -16.08 | 1.64 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 14.91m | 8.20% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 10.95m | 6.02% |
RA Capital Management LPas of 31 Mar 2024 | 6.86m | 3.77% |
HHLR Advisors Ltd.as of 31 Mar 2024 | 5.98m | 3.29% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.13m | 1.72% |
Wellington Management Co. LLPas of 31 Mar 2024 | 2.61m | 1.44% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 2.39m | 1.31% |
Westfield Capital Management Co. LPas of 31 Mar 2024 | 2.24m | 1.23% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 2.18m | 1.20% |
Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 1.98m | 1.09% |